Boothbay Fund Management, LLC Avrobio, Inc. Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.15 - $1.48 $41,172 - $52,986	35,802 Added 23.12%	190,635 $244,000
Q3 2023 Nov 14, 2023	BUY	$0.98 - $1.62 $125,378 - $207,257	127,937 Added 475.67%	154,833 $238,000
Q2 2023 Aug 14, 2023	BUY	$0.58 - $1.31 $15,599 - $35,233	26,896 New	26,896 $25,000
Q4 2020 Feb 12, 2021	SELL	$12.79 - $17.1 $210,254 - $281,106	-16,439 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$12.99 - $19.41 $213,542 - $319,080	16,439 New	16,439 $214,000
Q4 2019 Feb 14, 2020	SELL	$13.05 - $21.88 $561,189 - $940,905	-43,003 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.12 - $23.44 $607,202 - $1.01 Million	43,003 New	43,003 $607,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.